Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Yangsan
Clinical trial register · South Korea

Clinical Trials in Yangsan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Pusan National University Yangsan Hospital19 Novo Nordisk A/S11 AstraZeneca8 Novartis Pharmaceuticals5 Bayer5
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Yangsan

124 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Novo Nordisk A/S
Phase 3
400
Seoungnam-si, Suwon, Yangsan, Daegu, Seoul
2027-01-07
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Bucheon-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Busan, Daegu, Daejeon
2026-10-26
Not yet open
Pusan National University Yangsan Hospital
Not applicable
20
Yangsan
2026-10-01
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Busan, Jeonju, Seongnam, Seongnam-si, Seoul, Suwon, Yangsan
2026-09-29
Recruiting
AstraZeneca
Phase 3
950
Busan, Daegu, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul, Yangsan
2026-09-16
Recruiting
Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD
NCT07770867Autism Spectrum Disorder, Social Communication Disorder
Neudive Inc.
Not applicable
156
Daegu, Iksan, Seoul, Yangsan
2026-09-15
Recruiting
HB05P on Muscle Health
NCT07749118Sarcopenia, Possible Sarcopenia
Pusan National University Yangsan Hospital
Not applicable
80
Yangsan
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Anyang, Cheonan-si, Seoul, Wŏnju, Yangsan
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,500
Anyang, Bucheon-si, Daegu, Seoul, Yangsan
2026-08-19
Recruiting
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure
NCT07631156Heart Failure With Reduced Ejection Fraction, Heart Failure, Ventricular Dysfunction, Left
Kyungsub Song
Phase 4
80
Daegu, Seongnam-si, Suwon, Yangsan, Seoul
2026-08-12
Recruiting
Kimchi Powder on Gut Health
NCT07749092Irritable Bowel Syndrome - Diarrhoea
Pusan National University Yangsan Hospital
Not applicable
100
Yangsan
2026-08-03
Recruiting
AstraZeneca
Phase 3
2,000
Goyang-si, Guri-si, Gwangju, Gyeonggi-do, Seoul, Yangsan
2026-07-06
Recruiting
Pfizer
Phase 3
954
Daejeon, Anyang-si, Yangsan, Incheon, Seoul
2026-06-10
Recruiting
Bayer
Phase 3
117
Yangsan, Jongno, Seodaemun, Seoul
2026-06-01
Recruiting
Samsung Medical Center
Observational
396
Daegu, Daejeon, Seongnam-si, Yangsan, Incheon, Jeju City, Jeonju, Hwasun
2026-05-28
Recruiting
Pusan National University Yangsan Hospital
Not applicable
80
Yangsan
2026-05-15
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Wŏnju, Anyang-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Daegu, Daejeon
2026-05-11
Recruiting
Safety and Effectiveness of Ultrasound-guided Pharmacopuncture for Spinal Diseases
NCT07543692Spinal Disease, Neck Pain, Low Back Pain, Radiculopathy
Jaseng Medical Foundation
Observational
600
Daejeon, Seoul, Bucheon-si, Yangsan
2026-04-29
Recruiting
BioMarin Pharmaceutical
Phase 2/3
160
Seoul, Yangsan
2026-04-20
Recruiting
Novo Nordisk A/S
Phase 2
270
Ansan-si, Yangsan, Seoul
2026-04-17
Not yet open
Pusan National University Yangsan Hospital
Not applicable
80
Yangsan
2026-04-01
Recruiting
Yuhan Corporation
Phase 2
150
Gyeonggi-do, Daegu, Seoul, Yangsan, Incheon
2026-03-26
Not yet open
Gyeong-Jo Byeon, MD, PhD
Not applicable
80
Yangsan
2026-02-12
Recruiting
Eli Lilly and Company
Phase 3
1,980
Namdong-gu, Seogu, Seongnam, Seoul, Yangsan
2026-02-06
Recruiting
Pusan National University Yangsan Hospital
Not applicable
9
Yangsan
2026-02-01
Recruiting
AstraZeneca
Phase 3
1,100
Busan, Daegu, Goyang-si, Seongnam-si, Seoul, Suwon, Yangsan
2025-12-29
Active, closed
Pusan National University Yangsan Hospital
Not applicable
330
Yangsan
2025-12-22
Active, closed
Taiho Oncology, Inc.
Phase 3
360
Daegu, Seongnam-si, Suwon, Cheongju-si, Goyang-si, Pusan, Yangsan, Jinju
2025-12-22
Recruiting
GlaxoSmithKline
Phase 3
450
Seoul, Daegu, Seongnam-si Gyeonggi-do, Suwon Kyunggi-do, Yangsan
2025-12-03
Recruiting
Tau-MEDICAL Co., Ltd.
Not applicable
20
Daegu, Yangsan, Seoul
2025-11-20
Recruiting
Bayer
Phase 3
111
Yangsan, Jongno, Seodaemun, Seoul
2025-11-19
By invitation
Novo Nordisk A/S
Observational
500
Goyang-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Busan, Daegu, Daejeon
2025-11-10
Active, closed
Pusan National University Yangsan Hospital
Observational
45
Yangsan
2025-11-06
Active, closed
Novo Nordisk A/S
Phase 3
330
Yangsan, Gwangju, Seoul
2025-11-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Jeollanam-do, Yangsan, Busan, Daejeon, Seoul
2025-10-08
Recruiting
Pusan National University Yangsan Hospital
Not applicable
45
Yangsan
2025-09-23
Active, closed
Pusan National University Yangsan Hospital
Not applicable
60
Yangsan
2025-09-19
Recruiting
Bilix Co.,Ltd.
Phase 2
50
Daegu, Seongnam, Seoul, Yangsan
2025-08-26
Recruiting
Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
NCT06770543Primary Hypercholesterolemia or Mixed Dyslipidemia
Novartis Pharmaceuticals
Observational
1,500
Yangsan, Busan, Seoul, Taegu
2025-08-13
Recruiting
AbbVie
Phase 3
120
Yangsan, Seoul
2025-07-28
Active, closed
Aligos Therapeutics
Phase 2
200
Ansan, Busan, Seoul, Ulsan, Yangsan
2025-07-15
Recruiting
Incheon St.Mary's Hospital
Phase 4
160
Ansan, Busan, Chilgok, Chuncheon, Gwangju, Incheon, Seoul, Yangsan
2025-07-07
Active, closed
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
DrugsBemnifosbuvir-Ruzasvir·BEM/RZR·Sofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Seoul, Yangsan, Busan
2025-06-02
Not yet open
Next Biomedical Co., Ltd.
Not applicable
60
Cheongju-si, Daejeon, Gwangju, Sejong, Seoul, Yangsan
2025-06
Recruiting
GC Biopharma Corp
Phase 1/2
18
Yangsan, Seoul
2025-05-14
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Cheongju-si, Namdong-gu, Yangsan, Busan, Seoul
2025-04-24
Recruiting
Broccoli Sprout Extract for Cognitive Function
NCT07334366Cognitive Dysfunction, Cognitive Decline
Pusan National University Yangsan Hospital
Not applicable
100
Yangsan
2025-04-16
Recruiting
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
NCT06902545Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugZolbetuximab
Astellas Pharma Korea, Inc.
Observational
377
Goyang-si, Suwon, Yangsan, Hwasun Gun, Daejeon, Seoul
2025-04-03
Recruiting
AstraZeneca
Phase 3
11,300
Bucheon-si, Cheongju-si, Daegu, Seongnam-si, Seoul, Suwon, Wŏnju, Yangsan
2025-03-14
Recruiting
Incyte Corporation
Phase 3
600
Ansan-si, Busan, Incheon, Seoul, Yangsan
2025-02-28
Recruiting
Pusan National University Yangsan Hospital
Not applicable
15
Yangsan
2025-02-12
Recruiting
Dianthus Therapeutics
Phase 3
256
Daegu, Daejeon, Seoul, Uijeongbu-si, Yangsan
2025-02-10
Recruiting
Autonomic Dysreflexia in Spinal Cord Injuries: UDS Filling Speed Impact
NCT06211491Spinal Cord Injuries, Autonomic Dysreflexia, UDS Filling Speed
Pusan National University Yangsan Hospital
Observational
30
Yangsan
2025-01-08
Recruiting
Phospholipid-rich Dairy Extract for Cognitive Function
NCT07011680Cognitive Function, Cognitive Decline
Pusan National University Yangsan Hospital
Not applicable
100
Yangsan
2025-01-07
By invitation
Novo Nordisk A/S
Observational
840
Goyang-si, Busan, Chungcheongnam-do, Daejeon, Gyeonggi-do, Seoul, Yangsan
2024-11-19
Recruiting
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
NCT06257394Acute Lymphoblastic Leukemia, Pediatric
Hyoung Jin Kang
Phase 2
74
Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
2024-10-20
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Yangsan, Seoul
2024-10-17
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Cheongju-si, Namdong-gu, Hwasun, Goyang-si, Seongnam-si, Yangsan, Busan, Seoul
2024-10-07
Recruiting
Ferring Pharmaceuticals
Phase 3
250
Yangsan, Hwasun, Seoul
2024-10-01
Recruiting
Ferring Pharmaceuticals
Phase 3
454
Goyang-si, Yangsan, Hwasun, Seoul
2024-10-01
Active, closed
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814Duchenne Muscular Dystrophy
NS Pharma, Inc.
Phase 1/2
20
Yangsan, Seoul
2024-09-18
Recruiting
Bayer
Phase 3
555
Suwon, Jinju, Yangsan, Hwasun-gun, Chungcheongbuk-do, Jongno -Gu, Seoul
2024-08-28
Recruiting
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
NCT06184009Pediatric Acute Lymphoblastic Leukemia
Jae Wook Lee
Phase 2
370
Seoul, Incheon, Suwon, Yangsan
2024-08-10
Active, closed
Exercise Program for Individuals With SCI in Community
NCT06524453Spinal Cord Injuries, Exercise Program, Rehabilitation
Pusan National University Yangsan Hospital
Not applicable
58
Yangsan
2024-08-01
Active, closed
Jaseng Medical Foundation
Not applicable
250
Bucheon-si, Daejeon, Haeundae, Seoul, Yangsan
2024-07-07
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Bucheon-si, Goyang-si, Seongnam-si, Suwon, Yangsan, Busan, Cheongju-si, Daegu
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Bupyeong-gu, Yangsan, Busan, Deagu, Daejeon, Seoul
2024-06-10
Active, closed
Exelixis
Phase 2/3
600
Busan, Suwon, Yangsan, Jeonju, Seoul
2024-06-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Bupyeong-gu, Hwasun, Suwon, Yangsan, Daegu, Junggu, Incheon, Seoul
2024-05-24
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugsKeytruda·Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
410
Seoul, Yangsan, Daegu
2024-05-14
Active, closed
Sanofi
Phase 3
1,541
Daegu, Gwangju, Ansan-si, Seongnam-si, Suwon, Yangsan, Bupyeong-gu, Seoul
2024-05-08
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Chungcheongbuk Do, Daegu, Gyeonggi-do, Jeollanam-do, Seoul, Yangsan
2024-04-09
Recruiting
Ho Joon Im
Phase 2
90
Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
2024-04-04
Recruiting
Hee Young Ju
Phase 2
116
Seoul, Yangsan, Daegu, Daejeon, Hwasun, Jeju City, Seongnam, Suwon
2024-03-05
Active, closed
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT05996003Duchenne Muscular Dystrophy, Exon 44, DMD
DrugBrogidirsen
NS Pharma, Inc.
Phase 2
20
Seongnam-si, Yangsan, Seoul
2024-02-22
Active, closed
Regeneron Pharmaceuticals
Phase 3
216
Gyeonggi-do, Suwon, Yangsan, Jeonju, Incheon, Busan, Daegu, Seoul
2024-02-15
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
226
Busan, Anyang-si, Goyang-si, Seongnam-si, Suwon, Yangsan, Jeonju, Hwasun-gun
2024-01-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hwasun, Goyang-si, Seongnam, Suwon, Yangsan, Cheongju-si, Busan, Junggu
2023-11-12
Recruiting
Sanofi
Phase 3
180
Yangsan, Seoul
2023-10-10
Recruiting
Pusan National University Yangsan Hospital
Not applicable
126
Yangsan
2023-09-22
Recruiting
Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam
NCT05939674Flumazenil Adverse Reaction, Remimazolam, Hip Joint, Elderly Patients
DrugFlumazenil
Pusan National University Yangsan Hospital
Not applicable
24
Yangsan
2023-09-19
Recruiting
CrystalGenomics, Inc.
Phase 2
60
Anam, Anyang, Hwasun, Seoul, Yangsan
2023-08-23
Recruiting
Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients
NCT06202027FGF23-related Hypophosphataemic Rickets and Osteomalacia
Kyowa Kirin Korea Co., Ltd.
Observational
100
Wŏnju, Suwon, Yangsan, Gwangju, Sejong, Busan, Seoul
2023-08-11
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
148
Yangsan, Seoul, Daegu
2023-05-31
Active, closed
Sanofi
Phase 2
999
Ansan-si, Bucheon-si, Yangsan, Incheon, Seoul
2023-04-03
Recruiting
Seoul National University Bundang Hospital
Observational
1,240
Daegu, Gyeonggi-do, Hwasun, Ilsan, Jinju, Seongnam-si, Seoul, Yangsan
2023-04-01
By invitation
G7 Dual Mobility With Vivacit-E or Longevity PMCF
NCT05548972Hip Osteoarthritis, Rheumatoid Arthritis, Joint Diseases, Avascular Necrosis
Zimmer Biomet
Not applicable
358
Yangsan, Hwasun
2023-03-20
Active, closed
Novo Nordisk A/S
Phase 3
47
Yangsan, Seoul
2023-02-01
Recruiting
Bayer
Phase 3
100
Seongnam-si, Yangsan, Daegu, Seoul
2022-11-08
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Bucheon-si, Seongnam-si, Yangsan, Daegu, Daejeon, Incheon, Seongnam-si, Gyeonggi-do, Seoul
2022-11-01
Active, closed
Yonsei University
Observational
260
Busan, Chuncheon, Ansan-si, Goyang-si, Yongin-si, Daegu, Yangsan, Jeonju
2022-08-31
Active, closed
Sanofi
Phase 2/3
1,856
Daegu, Gwangju, Ansan-si, Seongnam-si, Suwon, Yangsan, Bupyeong-Gu, Seoul
2022-08-22
Active, closed
Novo Nordisk A/S
Phase 3
412
Yangsan, Sejong-si, Seoul
2022-08-10
Recruiting
CHA University
Not applicable
240
Cheonan, Ansan-si, Goyang-si, Seongnam-si, Yangsan, Changwon, Hwasun, Busan
2022-08-01
Recruiting
Pusan National University Yangsan Hospital
Observational
500
Yangsan
2022-06-09
Active, closed
Novartis Pharmaceuticals
Observational
683
Daegu, Wŏnju, Bucheon-si, Bundang Gu, Goyang-si, Yangsan, Jeonju, Suncheon
2022-05-09
Active, closed
Sanofi
Phase 3
104
Yangsan, Seoul
2022-05-03
Active, closed
Bayer
Phase 3
219
Seongnam-si, Yangsan, Daegu, Seoul
2022-03-28
Recruiting
AbbVie
Phase 3
768
Goyang-si, Seongnam, Suwon, Jinju, Yangsan, Cheongju-si, Seoul
2022-03-25
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Daegu, Wŏnju, Bundang Gu, Jinju, Yangsan, Incheon, Seoul, Cheongju-si
2021-11-23
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 3
626
Busan, Anyang-si, Goyang-si, Seongnam-si, Suwon, Daegu, Yangsan, Jeonju
2021-11-05
Recruiting
Corcym S.r.l
Observational
2,150
Seoul, Yangsan
2021-06-29
Active, closed
Incyte Corporation
Phase 3
899
Busan, Daegu, Goyang-si, Incheon, Jeonju, Jinju, Seoul, Yangsan
2021-05-11
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Goyang, Seongnam, Seoul, Yangsan
2021-03-18
Active, closed
Janssen Research & Development, LLC
Phase 2
220
Busan, Daegu, Goyang-si, Gwangju, Seoul, Yangsan
2020-12-18
Active, closed
AstraZeneca
Phase 3
358
Daegu, Hwasun-gun, Incheon, Seoul, Yangsan
2020-12-16
Active, closed
Janssen Research & Development, LLC
Phase 3
518
Busan, Daegu, Gangnam Gu, Goyang-si, Hwasun-gun, Namdong, Seoul, Yangsan
2020-12-07
Active, closed
Pfizer
Phase 3
114
Yangsan, Seoul
2020-11-05
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
160
Daegu, Seoul, Yangsan
2020-07-13
Active, closed
AstraZeneca
Phase 3
805
Goyang-si, Seoul, Suwon, Yangsan
2020-05-05
Active, closed
Actelion
Phase 3
138
Seoul, Yangsan
2020-01-16
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Cheongju-si, Jeonju, Namdong, Seoul, Yangsan
2019-09-17
Recruiting
Pusan National University Yangsan Hospital
Not applicable
60
Yangsan
2018-12-01
Active, closed
AbbVie
Phase 2
270
Goyang-si, Seongnam, Suwon, Yangsan, Incheon, Hwasun-gun, Cheongju-si, Seoul
2018-10-10
Recruiting
Novartis Pharmaceuticals
Observational
700
Daegu, Seongnam-si, Seoul, Yangsan, Yongin-si
2018-09-25
Active, closed
Seung-Jung Park
Observational
900
Bucheon-si, Seoul, Yangsan
2018-05-10
Active, closed
Janssen Research & Development, LLC
Phase 1/2
125
Daejeon, Gwangju, Gyeonggi-do, Seoul, Yangsan
2018-04-05
Active, closed
Ten Year Implant Survivorship of the ANTHEM™ PS Total Knee System
NCT03078543Arthroplasty, Replacement, Knee
Smith & Nephew, Inc.
Observational
148
Yangsan, Hwasan, Seoul
2017-06-28
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Seongnam-si, Yangsan, Hwasun-gun, Incheon, Seoul
2014-12-17
Active, closed
Gilead Sciences
Phase 3
90
Yangsan, Daegu, Seoul
2012-12-06
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Yangsan, Busan, Changwon, Cheongju-si, Daegu, Daejeon, Gangneung, Gwangju
2012-01
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Yangsan, Seoul, Daejeon
2004-09-15
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Suwon, Yangsan, Jeju City, Seoul, Busan, Daejeon
2001-07-31
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Yangsan, Seoul, Daejeon
1991-04-01
Rows per page Showing 1–124 of 124
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/yangsan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 124 of those studies with a site in Yangsan.

How many clinical trials are recruiting in Yangsan?

67 of the 124 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 6 have not yet opened recruitment, 48 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Yangsan), 124 studies
PhaseStudiesRecruitingShare
Phase 3552744.4%
Not applicable231418.5%
Observational211416.9%
Phase 215812.1%
Phase 1/2413.2%
Phase 2/3413.2%
Phase 4221.6%

Most active sponsors

Lead sponsors with the most studies (Yangsan)
Lead sponsorStudiesRecruiting
Pusan National University Yangsan Hospital1913
Novo Nordisk A/S112
AstraZeneca86
Bayer54
Novartis Pharmaceuticals52
Sanofi51
Janssen Research & Development, LLC40
Merck Sharp & Dohme LLC43
AbbVie32
Genzyme, a Sanofi Company33
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.